The Journal of Rehabilitation Research and Development · 2005 · 90 citations · 26 references
MedicineOrthopedic SurgeryBone MetabolismOrthopedicsSpinal Cord Injury RehabilitationBone HealthBone Metabolism PharmacotherapySpinal Cord InjurySpinal TraumaAcute Spinal Cord Injury CareBone Mineral DensityBone Mineral Density AssessmentBone Mineral LossDrug Effects On Bone DensityPlacebo ComparatorsPlacebo-controlled Efficacy AssessmentTraumatic Bone Loss
Eleven subjects participated in a prospective placebo-controlled trial to address the efficacy of pamidronate in reducing bone loss in persons with acute spinal cord injury (SCI). We administered pamidronate (treatment) or normal saline (placebo) intravenously at baseline (22 to 65 days after injury) and sequentially over 12 months, with follow-up at 18 and 24 months. Regional bone mineral density (BMD) was lost over time, regardless of group. In the treatment group compared with the placebo group, we noted a mild early reduction in loss of total leg BMD. Significant bone loss from baseline occurred earlier in the placebo group at the regional sites than in the treatment group. However, by the end of the treatment and follow-up phases, both groups demonstrated a similar percent bone loss from baseline. Despite an early reduction in bone loss, pamidronate failed to prevent major, long-term bone loss in persons with acute neurologically complete SCI.
26
Quantitative histological data on disuse osteoporosis
P Minaire, Pierre J. Meunier, C Edouard et al. · Calcified Tissue International · 1974 · 439 citations
Osteoporosis after spinal cord injury
Douglas E. Garland, Charles A. Stewart, Rodney H. Adkins et al. · Journal of Orthopaedic Research® · 1992 · 434 citations